With the power of new therapies, technologies, and big data, we are at a pivotal moment in clinical research. The opportunity to accelerate the discovery and development of treatments for patients with rare and deadly diseases is within reach.
The Global Coalition for Adaptive Research (GCAR) unites physicians, clinical researchers, advocacy and philanthropic organizations, biotech/pharma, health authorities, and other key stakeholders in healthcare with the intent to leverage master protocols and platform trials.
Master Protocols study multiple therapies or multiple disease sub-types simultaneously and/or over time.
Adaptive Platform Trials focus on a disease or condition, rather than a particular intervention. Uniquely designed as a long-standing clinical trial with the ability to test multiple therapies simultaneously against a common control (or standard of care), it can offer new therapies a much faster path for evaluation by leveraging the infrastructure already in place.
As innovative solutions, master protocols and platform trials align diverse stakeholders and provide more efficient, accelerated drug development to support patient care.
They deliver:
By developing and operationalizing innovative clinical trials with some of the world’s foremost clinical, translational, basic science investigators and trial experts — and as a 501(c)(3) non-profit — GCAR is uniquely positioned to foster the collaboration required to design and sponsor innovative trial designs.
UNLOCK THE FUTURE OF INNOVATION—DIVE INTO OUR LATEST WHITE PAPERS FOR EXCLUSIVE, CUTTING-EDGE INSIGHTS
